IMV : Corporate Presentation

Investor Presentation

November 2020

1

Developing a New Class of Immunotherapies and Vaccines

We are committed to making immunotherapy and vaccines more effective, more broadly applicable, and more widely available to patients.

TICKER

IMV (Nasdaq & TSX)

MARKET CAP (Nov.11)

• $US 270 M /
• $CAD 353 M

Cash and cash equiv. (Sept. 30): 54.7 M CDN$ / 40.9 M US $

OUTSTANDING SHARES (Nov.11)

Basic : 67.1M

Fully diluted : 71.6M

© 2020 IMV Inc. All rights reserved.

2

Investment Highlights

DPX™ delivery platform to create a novel class of vaccines and immunotherapies

Unique mechanism of action that generates targeted and sustained stimulation of immune system

Immune cell activation that can be maintained over an extended period with limited side effects

Clinically-demonstrated activity in solid / hematologic cancers as well as infectious diseases

DPX-Survivac, lead oncology program focused on unmet medical needs

Demonstrated tumor regression in solid and hematologic cancers

Excellent safety profile across all clinical Phase 1 and 2 studies (N=350)

DPX-COVID-19, our answer to the global pandemic

Designed to generate prolonged antiviral protection

Potential ability to serve an older / immunocompromised population

Fully synthetic formulation that allows rapid, cost-efficientscale-up manufacturing

Milestones

Additional phase 2 DPX Survivac combination clinical data in DLBCL at ASH (Dec. 6, 2020)

Update on DPX-Survivac/CPA in late-stage ovarian cancer (Dec. 3, 2020) and for the basket trial (Q1 2021)

Initiate DPX COVID-19 Phase 1/2 trial before year end 2020

© 2020 IMV Inc. All rights reserved.

3

Leadership Team with Strong Track Record in Drug Development

Frederic Ors, MSc, MBA			Marie-Eve Charrois, MA		Brittany Davison, CPA, CA
Chief Executive Officer			Vice President, Regulatory		Vice President, Finance
			Affairs

Pierre Labbé, CPA			Stephan Fiset, MSc, MBA		Ryan Marshall, MSc
Chief Financial Officer			Vice-President, Clinical		Vice President, Project
			Research		Management and Operations

Andrew Hall			Tariq Massad, PhD, PMP		Marianne Stanford, PhD
Chief Business Officer			Vice President, Process Dev		Vice-President, Research &
			and Manufacturing		Development

Joanne Schindler, DVM, MD			Annie Tanguay, BSc
Chief Medical Officer			Senior Vice President,
			Quality and Regulatory

© 2020 IMV Inc. All rights reserved.

4